Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934179 | 0.91 | TGM2 (0.45) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL9825827 | 0.89 | SLC7A5 (0.39) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL4656570 | 0.88 | TGM2 (0.35) | SLC7A5PTGS1KDM4EADORA3ALOX15 | |
| SCHEMBL9827314 | 0.86 | SLC7A5 (0.38) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL9826282 | 0.84 | TGM2 (0.43) | SLC7A5TGM2TYRITGB3ITGA2B | |
| SCHEMBL4936405 | 0.83 | TGM2 (0.38) | SLC7A5PTGS1KDM4ETGM2PKM | |
| SCHEMBL9825346 | 0.83 | TGM2 (0.38) | SLC7A5PTGS1KDM4ETGM2PKM | |
| SCHEMBL4933034 | 0.78 | TGM2 (0.44) | SLC7A5PTGS1TGM2GRIA2PKM | |
| SCHEMBL9826251 | 0.77 | L3MBTL1 (0.37) | TGM2ITGB3ITGA2BITGAV | |
| SCHEMBL9825868 | 0.77 | L3MBTL1 (0.36) | KDM4ETGM2ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | claimed |
| US-20080299170-A1 | Medical Devices and Coatings Therefor | ASTON UNIVERSITY (GB) | 2008-12-04 | — | — | US | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299170-A1 | Medical Devices and Coatings Therefor | F8, HABP2, TFPI | SLC7A5 3196/4885PTGS1 582/4885KDM4E 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.